Anónimo. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. U.S. Food and Drug Administration 2020:1. [Ref.ID 103663]

Anónimo. Troubles rétiniens d'origine médicamenteuse. Prescrire 2019;39:19-25. [Ref.ID 103005]

Anónimo. Maladies auto-immunes d'origine médicamenteuse. Prescrire 2017;37:346-53. [Ref.ID 101654]

Anónimo. Ruxolitinib et polycythémie essentielle. Prescrire 2016;36:246-50. [Ref.ID 100529]

Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, Farley MM. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015;61:1304-6. [Ref.ID 99556]

Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19. [Ref.ID 98960]

Anónimo. Siméprévir. Prescrire 2015;35:94-5. [Ref.ID 98910]

Quintana LF, Campistol JM. Interferón beta, microangiopatía trombótica y síndrome nefrótico. Med Clin (Barc) 2015;144:65-6. [Ref.ID 98708]

Lawitz E, Sulkowski MS, Ghalib R, Rodríguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkek-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-65. [Ref.ID 98325]

Gane E. Hepatitis C beware—the end is nigh. Lancet 2014;384:1557-60. [Ref.ID 98307]

Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C-Y, Chang T-T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C-J, Sievert W, Bronowicki J-P, Thabut D, Lee Y-J, Kao J-H, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, on behalf of the HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384:1597-605. [Ref.ID 98304]

Anónimo. Sofosbuvir. Actif sur le virus de l'hépatite C, mais une évaluation clinique incomplète. Prescrire 2014;34:726-32. [Ref.ID 98256]

Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Fisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R, for the VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001. [Ref.ID 97630]

Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, Podsadecki T, Reddy KR. ABT-450/r - Ombitasvir and dasabuvir with or for HCV. N Engl J Med 2014;370:1983-92. [Ref.ID 97629]

Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r - Ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82. [Ref.ID 97628]

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gómez M, Zarski J-P, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, for the ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98. [Ref.ID 97605]

Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW, for the ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88. [Ref.ID 97604]

Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med 2014;370:1869-71. [Ref.ID 97602]

Anónimo. Bocéprévir: atteintes hématologiques graves. Prescrire 2014;34:350. [Ref.ID 97560]

Liang TJ, Ghany MG. Therapy of hepatitis C. Back to the future. N Engl J Med 2014;370:2043-7. [Ref.ID 97487]